Thermo Fisher Scientific (TMO): Revisiting Valuation After New Alzheimer’s Registry and Ongoing Capital Deployment

Thermo Fisher Scientific (TMO) just enrolled the first patient into its new PPD CorEvitas Alzheimer's Disease Registry, a real world data initiative that quietly reinforces the stock's long term healthcare infrastructure story.

See our latest analysis for Thermo Fisher Scientific.

That backdrop of new registries and high productivity lab platforms lands in a stock that has already logged an 18.4% 90 day share price return and a 25.59% five year total shareholder return, which suggests that momentum is rebuilding after a softer patch.

If breakthroughs in Alzheimer’s data and bioprocessing are on your radar, it is worth exploring other healthcare names using our curated screen of healthcare stocks.

Yet with Thermo Fisher trading near 567 dollars, still sitting at a roughly 6 percent intrinsic discount and 12 percent below consensus targets, investors now have to ask: is this a fresh entry point, or is future growth already baked in?

Most Popular Narrative Narrative: 9.3% Undervalued

With Thermo Fisher last closing at 567.83 dollars against a narrative fair value near 626 dollars, the storyline leans toward a premium tools leader still priced at a discount.

The company's positioning as a trusted, end to end partner for pharma and biotech enables greater customer stickiness and deeper integration into high growth markets like clinical research, outsourcing (CDMO), and lab services, enhancing recurring revenue streams and supporting high single digit earnings growth over time.

Read the complete narrative.

Curious how steady but unspectacular growth, rising margins and a richer earnings multiple can still justify upside from here? The full narrative explains the underlying assumptions and calculations.

Result: Fair Value of $626 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, sustained funding pressure in academic and government labs, alongside ongoing China weakness, could easily temper the margin and growth story from here.

Find out about the key risks to this Thermo Fisher Scientific narrative.

Build Your Own Thermo Fisher Scientific Narrative

If the narrative above does not quite fit your view, you can dive into the numbers yourself and craft a tailored storyline in minutes, Do it your way.

A great starting point for your Thermo Fisher Scientific research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Do not stop at one opportunity. Put Simply Wall Street’s powerful screener to work and line up your next set of high conviction candidates before the crowd moves.

• Capture early stage growth potential by scanning these 3617 penny stocks with strong financials that already back their stories with solid financial foundations.
• Tap into the AI wave by reviewing these 25 AI penny stocks positioned at the intersection of innovation, scalability, and accelerating demand.
• Lock in quality income prospects with these 13 dividend stocks with yields > 3% that can support reliable cash returns while you focus on the bigger picture.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com